Clinical Research in Cardiology

, Volume 99, Issue 6, pp 393–400

Clinical outcomes in diabetic and non-diabetic patients with drug-eluting stents: results from the first phase of the prospective multicenter German DES.DE registry

  • Ibrahim Akin
  • Alexander Bufe
  • Steffen Schneider
  • Holger Reinecke
  • Lars Eckardt
  • Gert Richardt
  • Detlev Burska
  • Jochen Senges
  • Karl-Heinz Kuck
  • Christoph A. Nienaber
Original Paper

Abstract

Background

Patients with diabetes mellitus (DM) undergoing coronary revascularization are at increased risk for adverse outcomes. Without sufficiently powered data from diabetic subgroup analyses and in absence of randomized controlled trials in diabetic patients with primary clinical outcomes controversy is ongoing over safety and efficacy of drug-eluting stents (DES) in diabetic patients.

Methods and results

Between October 2005 and October 2006, 1,659 diabetic and 3,559 non-diabetic patients treated with DES (Paclitaxel or Sirolimus-eluting stents) were enrolled at 98 Drug-Eluting-Stent.DEutschland (DES.DE) sites. Major adverse cardiac and cerebrovascular events (MACCE), defined as the composite of death, myocardial infarction, and stroke, as well as target vessel revascularization (TVR) were defined as primary endpoints. The baseline clinical and descriptive morphology of coronary artery disease revealed more severe findings in diabetic patients. At 1-year follow-up, diabetic patients treated with DES had significantly higher rates for overall death (5.6 vs. 3.4%; p < 0.01), myocardial infarction (4.8 vs. 3.4%; p = 0.05), stroke (1.7 vs. 0.9%; p < 0.05), MACCE (10.9 vs. 7.1%; p < 0.001), and overall stent thrombosis (4.9 vs. 3.3%; p < 0.01) with slightly elevated rates for TVR (12.0 vs. 10.4%; p = 0.17); data which remained after risk-adjustment.

Conclusion

Data collected in DES.DE revealed that despite the use of DES the risk of myocardial infarction, death, and thrombotic events remains higher in diabetic patients.

Keywords

Diabetes mellitus PCI Stent thrombosis Restenosis Registry 

References

  1. 1.
    Bonow RO, Gheorghiade M (2004) The diabetes epidemic: a national and global crisis. Am J Med 116(Suppl 5A):2S–10SCrossRefPubMedGoogle Scholar
  2. 2.
    Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, Cosentino F, Jönsson B, Laakso M, Malmberg K, Priori S, Ostergren J, Tuomilehto J, Thrainsdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P, Qiao Q, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL, Deckers JW, Bertrand M, Charbonnel B, Erdmann E, Ferrannini E, Flyvbjerg A, Gohlke H, Juanatey JR, Graham I, Monteiro PF, Parhofer K, Pyörälä K, Raz I, Schernthaner G, Volpe M, Wood D (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. The Task Force and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for Study of Diabetes (EASD). Eur Heart J 28:88–136CrossRefPubMedGoogle Scholar
  3. 3.
    Drechsler K, Fikenzer S, Sechtem U, Blank E, Breithardt G, Zeymer U, Nienabuer J (2008) The EuroHeart Survey—Germany: diabetes mellitus remains unrecognized in patients with coronary artery disease. Clin Res Cardiol 97(6):364–370CrossRefPubMedGoogle Scholar
  4. 4.
    Abizaid A, Kornowski R, Mintz GS, Hong MK, Abizaid AS, Mehran R, Pichard AD, Kent KM, Satler LF, Wu H, Popma JJ, Leon MB (1998) The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 32:584–589CrossRefPubMedGoogle Scholar
  5. 5.
    Frye RL, August P, Brooks MM, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE, BARI 2D Study Group (2009) A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 360(24):2503–2515CrossRefPubMedGoogle Scholar
  6. 6.
    Abizaid A, Costa MA, Centemero M, Abizaid AS, Legrand VM, Limet RV, Schuler G, Mohr FW, Lindeboom W, Sousa AG, Sousa JE, van Hout B, Hugenholtz PG, Unger F, Serruys PW, Arterial Revascularization Therapy Study Group (2001) Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients. Insights from the Arterial Revascularization Therapy Study (ARTS) trial. Circulation 104:533–538CrossRefPubMedGoogle Scholar
  7. 7.
    Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabaté M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Jüni P (2007) Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370:937–948CrossRefPubMedGoogle Scholar
  8. 8.
    Mahmud E, Bromberg-Marin G, Palakodeti V, Ang L, Creanga D, Demaria AN (2008) Clinical efficacy of drug-eluting stents in diabetic patients. J Am Coll Cardiol 51:2385–2395CrossRefPubMedGoogle Scholar
  9. 9.
    Moussa I, Leon MB, Baim DS, O’Neill WW, Popma JJ, Buchbinder M, Midwall J, Simonton CA, Keim E, Wang P, Kuntz RE, Moses JW (2004) Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 109:2273–2278CrossRefPubMedGoogle Scholar
  10. 10.
    Hermiller JB, Raizner A, Cannon L, Gurbel PA, Kutcher MA, Wong SC, Russell ME, Ellis SG, Mehran R, Stone GW, TAXUS-IV Investigators (2005) Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus. The TAXUS-IV trial. J Am Coll Cardiol 45:1172–1179CrossRefPubMedGoogle Scholar
  11. 11.
    Stettler C, Allemann S, Wandel S, Kastrati A, Morice MC, Schömig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabaté M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, De Carlo M, Erglis A, Chechi T, Ortolani P, Schalij MJ, Diem P, Meier B, Windecker S, Jüni P (2008) Drug-eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ 337:a1331CrossRefPubMedGoogle Scholar
  12. 12.
    Dibra A, Kastrati A, Mehilli J, Pache J, Schühlen H, von Beckerath N, Ulm K, Wessely R, Dirschinger J, Schömig A, ISAR-DIABETES Study Investigators (2005) Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 353:663–670CrossRefPubMedGoogle Scholar
  13. 13.
    Jiménez-Quevedo P, Sabaté M, Angiolillo DJ, Alfonso F, Hernández-Antolín R, SanMartín M, Gómez-Hospital JA, Bañuelos C, Escaned J, Moreno R, Fernández C, Fernández-Avilés F, Macaya C, Alfonso F, Hernández-Antolín R, SanMartín M, DIABETES Investigators et al (2007) Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial. Eur Heart J 28:1946–1952CrossRefPubMedGoogle Scholar
  14. 14.
    Ortolani P, Ardissino D, Cavallini C, Bramucci E, Indolfi C, Aquilina M, Marzocci A (2005) Effect of sirolimus-eluting stent in diabetic patients with small coronary arteries (A SES-SMART Substudy). Am J Cardiol 96:1393–1398CrossRefPubMedGoogle Scholar
  15. 15.
    Silber S, Albertsson P, Avilles FF, Camici PG, Colombo A, Hamm C, Jørgensen E, Marco J, Nordrehaug JE, Ruzyllo W, Urban P, Stone GW, Wijns W, Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology (2005) Guidelines for percutaneous coronary interventions: the task force for percutaneous coronary interventions of the European society of cardiology. Eur Heart J 26:804–847CrossRefPubMedGoogle Scholar
  16. 16.
    World Health Organization (1999) Definition, diagnosis and classification of diabetes mellitus and its complication: report of a WHO consultation. Part 1. Diagnosis and classification of diabetes mellitus. World Health Organization, GenevaGoogle Scholar
  17. 17.
    Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW, Academic Research Consortium (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115:2344–2351CrossRefPubMedGoogle Scholar
  18. 18.
    Baumgart D, Klauss V, Baer F, Hartmann F, Drexler H, Motz W, Klues H, Hofmann S, Völker W, Pfannebecker T, Stoll HP, Nickenig G, SCORPIUS Study Investigators (2007) One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. J Am Coll Cardiol 50:1627–1634CrossRefPubMedGoogle Scholar
  19. 19.
    Garg P, Normand SHT, Silbaugh TS, Wolf RE, Zelevinsky K, Lovett A, Varma MR, Zhou Z, Mauri L (2008) Drug-eluting or bare-metal stenting in patients with diabetes mellitus. Results from the Massachusetts Data Analysis Center Registry. Circulation 118:2277–2285CrossRefPubMedGoogle Scholar
  20. 20.
    Weber FD, Schneider H, Wiemer M, Pfannebecker T, Tebbe U, Hamm CW, Senges J, Schneider S, Nienaber CA (2008) Sirolimus-eluting stent (Cypher) in patients with diabetes mellitus: results from the German Cypher Stent Registry. Clin Res Cardiol 97(2):105–109CrossRefPubMedGoogle Scholar
  21. 21.
    Schuhlen H, Kastrati A, Dirschinger J, Hausleiter J, Elezi S, Wehinger A, Pache J, Hadamitzky M, Schömig A (1998) Intracoronary stenting and risk for major adverse events during the first month. Circulation 98:104–111PubMedGoogle Scholar
  22. 22.
    Ong AT, Serruys PW, Aoki J, Hoye A, van Mieghem CA, Rodriguez-Granillo GA, Valgimigli M, Sonnenschein K, Regar E, van der Ent M, de Jaegere PP, McFadden EP, Sianos G, van der Giessen WJ, de Feyter PJ, van Domburg RT (2005) The unrestricted use of paclitaxel-versus sirolimus-eluting stents for coronary artery disease in an unrestricted population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol 45:1135–1141CrossRefPubMedGoogle Scholar
  23. 23.
    Iakovou I, Schmidt T, Bonizzoni E, GE L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A (2005) Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293:2126–2130CrossRefPubMedGoogle Scholar
  24. 24.
    Machecourt J, Danchin N, Leblanche JM, Fauvel JM, Bonnet JL, Marliere S, Foote A, Quesada JL, Eltchaninoff H, Vanzetto G, EVASTENT Investigators (2007) Rsik factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients. The EVASTENT matched-cohort registry. J Am Coll Cardiol 50:501–508CrossRefPubMedGoogle Scholar
  25. 25.
    Hoffmann R, Klinker H, Adamu U, Kelm M, Blindt R (2009) The risk of definitive stent thrombosis is increased after “off-label” stent implantation irrespective of drug-eluting stent or bare-metal stent use. Clin Res Cardiol 98(9):549–554CrossRefPubMedGoogle Scholar
  26. 26.
    Evangelista V, Totani L, Rotondo S, Lorenzet R, Tognoni G, De Berardis G, Nicolucci A (2005) Prevention of cardiovascular disease in type-2 diabetes: how to improve the clinical efficacy of aspirin. Thromb Haemost 93:8–16PubMedGoogle Scholar
  27. 27.
    Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW (2007) A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356:989–997CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Ibrahim Akin
    • 1
  • Alexander Bufe
    • 2
  • Steffen Schneider
    • 3
  • Holger Reinecke
    • 4
  • Lars Eckardt
    • 4
  • Gert Richardt
    • 5
  • Detlev Burska
    • 1
  • Jochen Senges
    • 3
  • Karl-Heinz Kuck
    • 6
  • Christoph A. Nienaber
    • 1
  1. 1.Divisions of Cardiology, Pulmonology, Department of Internal Medicine I, Intensive Care UnitUniversity Hospital Rostock, Rostock School of MedicineRostockGermany
  2. 2.Department of Cardiology, Helios Clinic WuppertalUniversity of Witten/HerdeckeWuppertalGermany
  3. 3.Department of CardiologyHeart Center LudwigshafenLudwigshafenGermany
  4. 4.Department of CardiologyUniversity Hospital MünsterMünsterGermany
  5. 5.Department of CardiologyHospital Bad SegebergBad SegebergGermany
  6. 6.Department of CardiologyAsklepios Hospital HamburgHamburgGermany

Personalised recommendations